ArticleThe AAPS journal2026
Charcoal-Based Depletion Method to Improve Drug Tolerance in Neutralizing Antibody Assays for Therapeutic Peptides.
Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide based therapeutics such as GLP-1 analogs are an increasingly important therapeutic modality for metabolic diseases. As these therapeutics often mimic endogenous counterparts, assessing their immunogenicity during clinical development is critical for understanding safety and efficacy profiles and meeting regulatory expectations. Here, we describe a sample pretreatment strategy using activated charcoal to deplete residual drug and mitigate matrix interference, enabling development of drug-tolerant neutralizing anti-drug-antibody (nAb) assays. This approach was optimized and validated using Survodutide, a half-life extended GLP-1R/GCGR dual-agonist currently in clinical development. The optimized charcoal depletion improved assay drug tolerance by approximately 100-fold, facilitating reliable nAb detection in clinical samples. Ultimately, the method was successfully implemented in several validated nAb assays to support Survodutide clinical development. This platform approach has the potential for broad application across peptide therapeutics where drug tolerance is a critical challenge.
Indexed as
Identifiers
42963450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.